Scarica l'app Stockscreener
26.24
0.08%
0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AMPH Giù?
Forum
Previsione
Precedente Chiudi:
$26.22
Aprire:
$26.25
Volume 24 ore:
120.12K
Relative Volume:
0.31
Capitalizzazione di mercato:
$1.20B
Reddito:
$722.68M
Utile/perdita netta:
$134.71M
Rapporto P/E:
9.8277
EPS:
2.67
Flusso di cassa netto:
$109.94M
1 W Prestazione:
+0.92%
1M Prestazione:
-3.95%
6M Prestazione:
+22.90%
1 anno Prestazione:
-27.39%
Intervallo 1D:
$26.19
$26.92
Intervallo di 1 settimana:
$25.42
$26.92
Portata 52W:
$20.39
$37.66
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Nome
Amphastar Pharmaceuticals Inc
Settore
Telefono
909-980-9484
Indirizzo
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Confronta AMPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
26.22 | 1.20B | 722.68M | 134.71M | 109.94M | 2.67 |
|
ZTS
Zoetis Inc
|
123.90 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.22 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-08-12 | Aggiornamento | Needham | Hold → Buy |
| 2025-05-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-02-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | Iniziato | Wells Fargo | Equal Weight |
| 2024-03-05 | Iniziato | JP Morgan | Overweight |
| 2023-11-17 | Iniziato | BofA Securities | Neutral |
| 2023-07-25 | Ripresa | Jefferies | Buy |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-07-29 | Iniziato | CapitalOne | Overweight |
| 2022-01-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | Iniziato | Northland Capital | Outperform |
| 2019-03-13 | Downgrade | Needham | Buy → Hold |
| 2019-03-13 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-03-13 | Reiterato | Needham | Buy |
| 2017-12-01 | Reiterato | Needham | Buy |
| 2017-11-09 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | Reiterato | Needham | Buy |
| 2017-03-14 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | Reiterato | Needham | Buy |
| 2016-05-10 | Reiterato | Needham | Buy |
| 2016-02-19 | Iniziato | Wells Fargo | Outperform |
| 2015-06-19 | Reiterato | Needham | Buy |
| 2015-06-03 | Iniziato | Raymond James | Strong Buy |
| 2014-07-21 | Iniziato | Needham | Buy |
Mostra tutto
Amphastar Pharmaceuticals Inc Borsa (AMPH) Ultime notizie
How Amphastar Pharmaceuticals Inc. (AMPH) Affects Rotational Strategy Timing - Stock Traders Daily
Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock? - sharewise.com
Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving - Finviz
A Look At Amphastar Pharmaceuticals (AMPH) Valuation After The AMP-110 License Agreement With Nanjing Hanxin - Yahoo Finance
Amphastar Pharmaceuticals Touts Shift to Proprietary Drugs, Teases AMP-007 Launch and Baqsimi Growth - MarketBeat
2 Reasons to Avoid AMPH and 1 Stock to Buy Instead - Finviz
Aug Opening: Will Amphastar Pharmaceuticals Inc stock recover faster than peers2025 Price Targets & Smart Investment Allocation Tips - Bộ Nội Vụ
Earnings Recap: Will Amphastar Pharmaceuticals Inc stock pay special dividends2025 Big Picture & Capital Protection Trade Alerts - Bộ Nội Vụ
Amphastar licenses synthetic ACTH analog for inflammatory conditions By Investing.com - Investing.com Nigeria
Amphastar Pharmaceuticals, Inc. (AMPH): Investor Outlook With A 7.39% Upside Potential - DirectorsTalk Interviews
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today - Finviz
Amphastar Licenses ACTH Analog AMP-110 for North America - TipRanks
Amphastar Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
Amphastar, Hanxin Enter Exclusive License Agreement for AMP-110 - Contract Pharma
Amphastar licenses synthetic ACTH analog for inflammatory conditions - Investing.com
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound - ACCESS Newswire
New synthetic hormone treatment targets autoimmune and inflammatory conditions - Stock Titan
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Could Be Riskier Than It Looks - 富途牛牛
The Bull Case For Amphastar Pharmaceuticals (AMPH) Could Change Following New BofA Coverage And JPM Spotlight - Yahoo Finance
Is Amphastar Pharmaceuticals Inc. stock a smart buy before Fed meetingExit Point & Daily Profit Focused Screening - Улправда
(AMPH) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Is Amphastar Pharmaceuticals (AMPH) Attractively Priced After Recent Share Price Weakness? - Sahm
Amphastar Pharmaceuticals, Inc. $AMPH Stock Holdings Trimmed by CX Institutional - MarketBeat
Why Amphastar Pharmaceuticals Inc. stock remains undervaluedJuly 2025 PostEarnings & Expert-Curated Trade Recommendations - Улправда
Assessing Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Momentum - Sahm
Will Amphastar Pharmaceuticals Inc. stock benefit from AI adoption2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Is Amphastar Pharmaceuticals Inc. stock affected by interest rate hikesWeekly Profit Report & High Return Trade Opportunity Guides - ulpravda.ru
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference - ACCESS Newswire
Amphastar Expands BAQSIMI® Distribution in Asia - MSN
Value Recap: Is Amphastar Pharmaceuticals Inc stock trading near support levels2025 Technical Patterns & Weekly Breakout Watchlists - moha.gov.vn
Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Pacer Advisors Inc. - MarketBeat
What analysts say about Amphastar Pharmaceuticals Inc stockTake Profit Strategies & Outstanding Investment Portfolio - earlytimes.in
Amphastar Director Sells 16,679 Shares for $441,800 - AOL.com
Amphastar Pharmaceuticals Inc Stock Analysis and ForecastVolatility Index Analysis & Swing Trade Smarter With Data Insights - earlytimes.in
Will Amphastar Pharmaceuticals Inc. stock split again soonStock Screening Results & Make Confident Moves With Forecasting Models - bollywoodhelpline.com
Is Amphastar Pharmaceuticals Inc stock affected by interest rate hikesShort Setup & Reliable Intraday Trade Alerts - moha.gov.vn
How supply chain issues affect Amphastar Pharmaceuticals Inc. stockInstitutional Holding Changes & Minimal Investment Portfolio - bollywoodhelpline.com
Responsive Playbooks and the AMPH Inflection - Stock Traders Daily
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
129,339 Shares in Amphastar Pharmaceuticals, Inc. $AMPH Purchased by Rice Hall James & Associates LLC - MarketBeat
Squarepoint Ops LLC Lowers Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals’ Resilient Q3 2025 Earnings Call - MSN
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring a Potential 16.08% Upside for Investors - DirectorsTalk Interviews
A Fresh Look at Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Stabilisation - Sahm
Will Amphastar Pharmaceuticals Inc. stock outperform international peersJuly 2025 Review & Community Trade Idea Sharing Platform - Улправда
Can Amphastar’s Recent Rebound Signal a Compelling Opportunity in 2025? - Sahm
Amphastar Pharmaceuticals Inc Azioni (AMPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amphastar Pharmaceuticals Inc Azioni (AMPH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 17 '25 |
Sale |
26.20 |
9,787 |
256,379 |
138,043 |
| Petersen Floyd F. | Director |
Dec 12 '25 |
Sale |
25.92 |
2,426 |
62,888 |
71,368 |
| Petersen Floyd F. | Director |
Dec 11 '25 |
Sale |
25.69 |
1,737 |
44,620 |
73,794 |
3.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):